Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist?

Keyphrases

• Tuberculosis 100%
• Anti-TNF Therapy 100%
• Rheumatoid Arthritis 60%
• Screening Test 40%
• Infliximab 40%
• Radiological Findings 20%
• Clinical Outcomes 20%
• Negative Effects 20%
• Autoimmune Systemic Diseases 20%
• Mechanism of Action 20%
• Disease-modifying Antirheumatic Drugs (DMARDs) 20%
• Novel Therapies 20%
• Routine Screening 20%
• Latent Tuberculosis 20%
• Associated Morbidity 20%
• Multiple Infections 20%
• Latent Tuberculosis Infection 20%
• Disseminated Tuberculosis 20%
• Diarthrodial Joint 20%
• Multidrug Therapy 20%
• Pathological Findings 20%
• Anti-tuberculosis Drugs 20%
• Tuberculosis Incidence 20%
• Older Female Patient 20%

Medicine and Dentistry

• Tumor Necrosis Factor 100%
• Inflammatory Arthritis 60%
• Rheumatoid Arthritis 60%
• Infliximab 40%
• Latent Tuberculosis 40%
• Mixed Infection 20%
• Systemic Autoimmune Disease 20%
• Disease Modifying Antirheumatic Drug 20%
• Drug Therapy 20%
• Screening Test 20%
• Play Therapy 20%
• Miliary Tuberculosis 20%
• Polypharmacy 20%
• Tuberculostatic Agent 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Rheumatoid Arthritis 60%
• Inflammatory Arthritis 60%
• Latent Tuberculosis 40%
• Infliximab 40%
• Systemic Disease 20%
• Pharmacotherapy 20%
• Mixed Infection 20%
• Disease Modifying Antirheumatic Drug 20%
• Polypharmacy 20%
• Tuberculostatic Agent 20%
• Miliary Tuberculosis 20%